A Study on Sensitivity of Cord Blood Bilirubin Level in Predicting Neonatal Hyperbilirubinemia. by Mary Reena, C
A STUDY ON SENSITIVITY OF CORD BLOOD 
BILIRUBIN LEVEL  IN PREDICTING 
NEONATAL HYPERBILIRUBINEMIA 
Dissertation submitted to 
THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY, 
CHENNAI 
With partial fulfillment of the regulations 
For the award of the degree of 
MD BRANCH IV 
PAEDIATRIC MEDICINE 
GOVT.KILPAUK MEDICAL COLLEGE & HOSPITAL, 
CHENNAI 
 
 
 
 
 
 
THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY, 
CHENNAI, TAMILNADU 
 
APRIL 2017 
 
 CERTIFICATE 
 
Certified that this dissertation entitled “A STUDY ON SENSITIVITY 
OF CORD BLOOD BILIRUBIN LEVEL IN PREDICTING NEONATAL 
HYPERBILIRUBINEMIA” is a bonafide work done by DR. MARY REENA 
.C, Postgraduate student of Paediatric Medicine, Government Kilpauk Medical 
College & Hospital, during academic year 2014-2017. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DECLARATION  BY THE GUIDE 
 
Prof.Dr.B.SATHYAMURTHY,  
   M.D., D.C.H., 
Professor and HOD 
Department of Paediatrics 
Kilpauk Medical College and Hospital, 
Chennai - 10 
 
Prof.Dr.R.NARAYANA BABU, M.D., D.C.H., 
DEAN 
Kilpauk Medical College and Hospital, 
Chennai - 10 
 
Certified that this dissertation entitled “A STUDY ON SENSITIVITY 
OF CORD BLOOD BILIRUBIN LEVEL IN PREDICTING NEONATAL 
HYPERBILIRUBINEMIA” is a bonafide work done by DR. MARY REENA 
.C, Postgraduate student of Paediatric Medicine, Government Kilpauk Medical 
College & Hospital, during academic year 2014-2017. 
 
 
 
 
 
 
 
 
  
Prof.Dr.A.T.ARASAR SEERALAR, 
   M.D.,D.C.H. 
Professor of Paediatrics 
Department of Paediatrics 
Kilpauk Medical College and Hospital, 
Chennai - 10 
 
 DECLARATION 
 
I declare that this dissertation entitled “A STUDY ON SENSITIVITY 
OF CORD BLOOD BILIRUBIN LEVEL IN PREDICTING NEONATAL 
HYPERBILIRUBINEMIA” has been conducted by me at Government 
Kilpauk Medical College and Hospital. It is submitted in the fulfillment of the 
award of the degree of M.D (Paediatrics for the April 2017 examination to be 
held under The Tamilnadu DR.M.G.R Medical University, Chennai. This 
has not been submitted by me for the award of any degree or diploma from any 
other university. 
 
 
PLACE: 
DATE :                                                                   (Dr.C.MARY REENA) 
                                          
 
 
 
 
 
ACKNOWLEDGEMENT 
         I express my sincere thanks to Prof.Dr.R.NARAYANA BABU, M.D., D.C.H., 
Dean Government Kilpauk Medical college and Hospital, for allowing me to conduct 
this study using the available facilities. 
I am greatly indebted to Prof.Dr.A.T.ARASAR SEERALAR, M.D., D.C.H, 
Professor, Department of Paediatrics , Govt. Kilpauk Medical College and Hospital, 
who was my guide for the dissertation. I thank him whole heartedly for his able 
guidance and encouragement throughout the study. 
       I am indebted to Prof.Dr.B.SATHYA MURTHY, M.D.,D.C.H., Professor and 
HOD, Department of Paediatrics, Kilpauk Medical college and Hospital, for his 
valuable support through the study. 
I am immensely greatful to Prof.Dr.K.DEVI MEENAKSHI M.D., D.C.H., 
Professor Department of Paediatrics for her encouragement and support given for my 
study. 
I would like to thank the Assistant professors of Department of Paediatrics, 
Kilapuk medical college & hospital Dr.AADALARASAN, M.D, D.C.H, 
Dr.SUNDAR, M.D., Dr.SRIDEVI M.D, D.C.H, Dr.RAJAVIJAYAKRISHNAN, 
M.D, D.C.H, Dr.RAJI, M.D, D.C.H, Dr.SUGANYAM.D, D.C.H., 
Dr.SELVAKUMARD.A, M.D for their invaluable suggestions and guidance 
throughout the study. 
I also thank  Department of Obstetrics and Gynaecology, Biochemistry and 
Statistician  for their valuable support throughout my dissertation work. 
I also thank my colleagues, friends and staff of our hospital for their support. 
Finally I would like to thank the parents of the newborns who wholeheartedly 
gave their consent on behalf of their wards for this study and the newborns who bore 
the pain of venipuncture without whom this study wouldnot have been possible. 
  
   
  
Digital Receipt 
This receipt acknowledges  that  Turnitin received your paper. Below you will  find the 
receipt information regarding your  submission. 
The first page of  your submissions is  displayed below. 
 
Submission author: 201417153 Md Paediatrics mary reena 
Assignment title: 2015- 2015 plagiarism 
Submission title: thesis final 
File name: THESIS_FINAL.docx 
File size: 566.62K 
Page count: 80 
Word count: 8,366 
Character count: 50,274 
Submission date: 23- Sep- 2016 10:46PM 
Submission ID: 709123284 
  
CONTENTS 
S.No Chapter  Page no. 
1. INTRODUCTION  1 
2. REVIEW OF LITERATURE 47 
3. AIMS AND OBJECTIVES 55 
4. MATERIALS AND METHODS 56 
5. RESULTS AND ANALYSIS 60 
6. DISCUSSION 77 
7. CONCLUSION 82 
 ANNEXURES  
  BIBLIOGRAPHY  
  PROFORMA  
  INFORMED CONSENT  
  ETHICAL COMMITTEE 
CERTIFICATE 
 
  ABBREVIATION  
  MASTER CHART  
 
 
 
INTRODUCTION 
Neonatal  hyperbilirubinemia is a major concern for both parents and  
pediatricians. Hence early discharge of healthy term neonates  after delivery has 
become a common practice because of social,  medical ,economic constraints 
[1]
. 
But an association between early discharge and the risk of re admission to the 
hospital has been increased 
[2]
 
Neonatal hyperbilirubinemia is the most common cause for readmission 
during early new born period 
3
. Hence the early  recognition,   follow-up, and  
treatment of jaundice has become more important.  Severe jaundice requiring 
exchange transfusion  and kernicterus, can occur in some full-term healthy 
neonates discharged early with no apparent findings of hemolysis
4
. The 
American Academy of Pediatrics recommends that neonates  discharged within 
48 hours should have a follow-up visit after 48 to 78 hours to  detect early 
neonatal hyper bilirubinemia 
5
. But however this is not possible in our country 
due to limited followup facilities in the locality . Hence the concept of 
prediction of neonatal hyper bilirubinemia in early stage is an attractive option. 
A reliable and  clinically evaluated method for estimation of serum  
bilirubin dependent brain damage is still lacking [
6,7
]. Measurement of the 
serum bilirubin clinically is not reliable 
8
  In order to  implement early 
detection,  treatment and prevention of  bilirubin dependent brain damage, 
indicates the necessity to  predict the risk of jaundice in initial stage. The 
present study was conducted in healthy term neonates to find out the sensitivity 
of cord blood bilirubin in predicting neonatal hyperbilirubinemia. 
1) To study the sensitivity of cord blood bilirubin level in predicting 
neonatal hyperbilirubinemia. 
2) To find out mean cord blood bilirubin level. 
DEFINITION  
Neonatal Jaundice or Neontal Hyperbilirubinemia or Neonatal Icterus 
(ἴκτερος)-  is defined as yellowish staining of the skin and mucous membranes / 
sclera by bilirubin. 
PREVALANCE OF NEONATAL HYPERBILIRUBINEMIA 
            About 60%  term infants & 80 %  preterm neonates develop jaundice 
during neonatal period
. (10)
. The present study showed the incidence of neonatal 
hyperbilirubinemia was 22.80%. In various studies it was between 13-25%. 
  
PHYSIOLOGY OF BILIRUBIN PRODUCTION  
Bilirubin production 
The breakdown product of haeme is bilirubin.
(11)
 and it occurs in the 
 phagocytic cells of RES.  Heme oxygenase acts on heme and  opens up  the 
tetrapyrole ring of heme  to produce biliverdin ,carbon monoxide. The enzyme 
biliverdin reductase catalyze the conversion of biliverdin to bilirubin. 
From non hemoglobin sources1mg/kg of bilirubin was .    
produced(cytochromes,myoglobin,catalases).   
  
METABOLISM OF HEME TO BILIRUBIN 
 
In intrauterine life the fetus requires a good haemoglobin concentration to 
take oxygen effectively from maternal blood and to get delivered to the fetal 
tissues. Immediately after delivery, with a good supply of oxygen from their 
own lungs, the requirement of oxygen is dropped significantly. The red blood 
cell of neonates have reduced life span of about 90 days compared to  adults.
3
 . 
Following delivery, a significant proportion of neonates may have additional 
haemoglobin to dispose of as a result of bruising or other losses.  
Cytokines can induce heme oxygenase which causes increased 
breakdown of heme.
5
  In preterm infants already suffering from respiratory 
distress syndrome,there will be additional load of bilirubin due to cytokine 
release
.6
 
Forms of bilirubin found in plasma 
 An unravelled product of haem is bilirubin.which has three dimensional 
structure,  and hence in the metabolism of bilirubin  the amount of exposed 
reactive groups is significant.
7
 Due to internal hydrogen bonding,  the 
predominant form in neonates is ZZ bilirubin, which is a three-dimensional 
structure having the mirror image as the ring structure of the parent heme 
molecule (Figure 2).  
                                     STRUCTURE OF BILIRUBIN 
 
ZEbilirubin and  EZ-bilirubin (cyclobilirubin) are produced as the result 
of rotation  involving pyrrole rings which accounts for  about 14% and <1%, 
respectively, of circulating bilirubin in  neonates8 ZE bilirubin and EZ bilirubin 
isomers have a more open configuration.The reactive groups are exposed so 
they are readily soluble.These type of bilirubin is formed as a result of 
phototherapy.. 
Albumin bound unconjugated bilirubin with the binding affinity of 10 to 
10
M 
is transported in plasma. which is non toxic and does not cross the blood 
brain barrier. Bilirubin can bind with other proteins such as lipoproteins, alpha-
fetoprotein and ligandin. Lysine plays  a major role in in binding of bilirubin to 
ligandin and albumin . Recent studies suggest that modulation in bilirubin 
toxicity is due to lysine. 
Bilirubin dissociated from albumin is taken up by facilitated diffusion 
into the hepatocytes and bind with cytosolic glutathione-s- transferase (ligandin) 
which keeps it soluble and prevents its efflux. Bilirubin conjugation is essential 
for efficient biliary excretion and glucuronidation of bilirubin is catalysed by 
isoform of Uridinediphoshoglucuronate Glucuronyl Transferase, termed 
UGT1A1. Direct bilirubin  is  not absorbed in the intestine and secreted in to 
second part of duodenum after being stored in gall bladder. 
Direct bilirubin  is reduced to stercobilinogen by gut bacteria and it  is 
excreted in feces. The newborn gut is devoid of gut bacteria and the enzyme 
glucuronidase converts the conjugated bilirubin into unconjugated bilirubin 
which gets reabsorbed into the systemic circulation and it is known as 
Enterohepatic circulation. Glucuronidase enzyme is destroyed by intestinal 
bacteria. Bilirubin is also present in the meconium of which half of this is 
unconjugated bilirubin and it is reabsorbed. Indirect bilirubin in the fetus is 
removed  by crossing the placenta or  fetal liver. 
Polar compounds such as Conjugated bilirubin is unable to penetrate  the  
placental membrane. But non polar compounds can diffuse easily. The 
transplacental gradient between fetus and mother is 5:1 to 10:1. Around 12
th
 
week of gestation, Bilirubin is present  in amniotic fluid but after 36 to 37 
weeks of gestation it disappears.  Fetus also swallows some amount of bilirubin 
from amniotic fluid. Biliverdin does not cross the placenta,so biliverdin gets 
converted in to bilirubin 
12 
 
  
PHYSIOLOGIC HYPERBILIRUBINEMIA 
 12
  
Neonates are more prone for hyperbilirubinemia due to the following 
factors: 
1. Increased bilirubin production due to decreased RBC survival and 
increased RBC volume per kg, Increased ineffective erythropoesis and 
increased turn over of non hemoglobin heme proteins.  
2. Increased entero-hepatic circulation by high levels of beta-glucuronidase, 
Decreased intestinal bacteria, Decreased gut motility with poor excretion 
of meconium. 
3.  Defective uptake of bilirubin from plasma by decreased ligandin and 
binding of anions to ligandin. 
4. Defective conjugation due to decreased uridine diphosphogluconurate 
glucuronosyl transferase. 
5. Decreased hepatic excretion of bilirubin  
ETIOLOGY OF PATHOLOGICAL HYPERBILIRUBINEMIA:  
I) Increased bilirubin load – Hemolytic Jaundice 
Hemolysis occurs due to either immune or non-immune mechanisms. In 
this case, unconjugated bilirubin levels will be increased. 
i) Immune mediated hemolysis(RH incompatability and ABO 
incompatability) 
1) Rh is an antigen carried only on RBCs. When a Rh negative woman 
carries a Rh positive fetus, she develops antibodies to the fetal Rh antigen 
on fetal RBCs. Maternal exposure may occur  through blood transfusions, 
feto-maternal hemorrhage, amniocentesis or abortion. Once sensitized, 
there will be transplacental passage of Immunoglobulin IgG against the 
fetal antigens resulting in immune destruction of fetal RBCs. Modified 
liley’s chart can be used for the antenatal  prediction of Rh 
isoimmunisation. In this chart optical density difference is plotted against 
gestational age.  
 
MODIFIED LILEY’S CHART 
  
2) ABO incompatibility  
       A and B are two major erythrocyte membrane antigens. The cause of 
hemolysis is due to the reaction of maternal anti-A or anti-B antibodies directed 
against fetal antigens. It is usually seen in babies having A or B blood group 
born to O blood group mothers.  
ii) Non immune mediated hemolysis 
1. RBC Enzyme Defects 
i) G6PD Deficiency: X linked mode of inheritance leading to defect 
in NADPH production. This defect makes RBCs more vulnerable 
to lysis under oxidative stress conditions 
 ii) Pyruvate Kinase Deficiency: This enzyme deficiency prevents ATP 
formation causing cellular death and hemolysis. 
2. RBC Membrane Defects 
Hereditary spherocytosis, Elliptocytosis, Stomatocytosis, Pyknocytosis –  
In all these conditions  RBC  with abnormal  shape are trapped in the spleen. 
3. Hemoglobinopathies 
Alpha Thalassemia involves the production of abnormal globin rings that 
destroy the RBCs. 
 
II) INCREASED BILIRUBIN LOAD-NONHEMOLYTIC CAUSES 
It maybe due to polycythemia,breakdown of extravascular 
blood,increased enterohepatic circulation. 
A) POLYCYTHEMIA- ( Hematocrit more than 65%) 
Causes include preeclampsia of mother, Twin to twin transfusion, 
delayed cord clamping, Placental red cell transfusion, maternal to fetal 
transfusion, cord stripping, baby holding  below the mother at delivery, forceful 
uterine contractions before cord clamping. 
B) PLACENTAL INSUFFICIENCY 
Intrauterine growth retardation, post term infants, mother suffering from 
heart disease, pulmonary disease, maternal smoking, mother’s living in high 
altitude 
C) LUCEY-DRISCOLL SYNDROME 
It occurs due to the transfer of glucuronyl transferase inhibiting substance 
from the mother. Rarely it produces severe unconjugated hyperbilirubinemia.
75 
D) MISCELLANEOUS CAUSES 
Infant of diabetic mother, large for gestational age, congenital adrenal 
hyperplasia, beckwith widemann syndrome, neonatal thyrotoxicosis, congenital 
hypothyroidism, trisomy21, trisomy13, trisomy18, maternal use of propanolol, 
sepsis. 
III) INCREASED ENTEROHEPATIC CIRCULATION 
swallowed blood, cysticfibrosis, Pyloric stenosis, hirschprung disease, 
meconium ileus, meconium plug syndrome, paralytic ileus, intestinal atresia. 
C) EXTRAVASCULAR BLOOD 
Cephal hematoma, subgaleal hematoma, extensive bruising. 
 CEPHALHEMATOMA 
It occurs as a result of birth injury.There is collection of blood below the 
periosteum as a result of ruputure of superficial veins.The swelling is fluctuant 
in nature which is limited by suture lines.There may be change in the color of 
the skin over the swelling.Most commonly seen over the parietal 
region.Appears immediately after birth or  after one to two days.It disappears 
after few days or few weeks depending on their size.Incision is required when 
the cephalohematoma is infected or it is the main cause of severe 
hyperbilirubinemia. 
SUBGALEAL HAEMORRHAGE 
Vacuum extraction is the main cause for subgaleal hemorrhage.There is 
collection of blood in the galea aponeurotica layer of scalp.The haemorrhage 
can extend into entire calvarium, resulting in ecchymosis,   periorbital edema.  
To stop further bleeding pressure dressing can be used. 
III) IMPAIRED BILIRUBIN CONJUGATION 
( 10)
 
A) CRIGLER NAJJAR SYNDROME TYPE I 
This Autosomal recessive disorder occurs due to absence of glucuronyl 
transferase(UGT1A1) activity. severe unconjugated hyperbilirubinemia  occurs 
in the first week of life and passage of pale yellow stools. Hemolysis is not 
present in this syndrome. 
DIAGNOSIS 
Increased bilirubin levels, absence of hemolysis and there will be 
decreased amount of bilirubin in bile. Definitive diagnosis is by measuring 
hepatic glucuronyl transferase activity by closed biopsy. 
B) CRIGLER NAJJAR SYNDROME TYPE 2 
This Autosomal recessive disorder occurs due to partial glucuronyl 
transferase deficiency. uncongugated hyperbilirubinemia occurs in first 3 days 
of life. Kernicterus  donot  occur usually.stool color is normal. hemolysis is not 
present. 
DIAGNOSIS 
Increased bilirubin levels, absence of hemolysis, liver enzymes and liver 
synthetic function tests are normal. 
C) GILBERT SYNDROME 
Due to mildly reduced activity of UDP-GLUCORONYL 
TRANSFERASE activity. Relatively common form of unconjugated 
hyperbilirubinemia  during periods of illness or stress.It is a risk factor for 
pigment gallstones. 
D) CONGENITAL HYPOTHYROIDISM 
Hyberbilirubinemia occurs due to impaired gut motility, delayed 
maturation of glucuronide conjugation, poor feeding. 
E) BREASTFEEDING JAUNDICE  12  
Incidence is 12% to 13% in breast fed infants 
IT is common in breast fed infants than formula fed infants. It occurs due 
to decreased intake of breast milk hence decreased gut motility and increased 
enterohepatic circulation. 
F) BREASTMILK JAUNDICE ( 12 ) 
Incidence in term infants is 2% to 4%. It is of late onset and peaks by 14 
days of life, occurs due to3-alpha,20 preganendiol compound in breastmilk 
which interferes with bilirubin metabolism.The bilirubin levels will be elevated 
if breastfeeding is continued and levels will fall by 4 to 12  weeks of age. 
IV) IMPAIRED BILIRUBIN EXCRETION 
Anatomical abnormalities or functional abnormalities can cause impaired 
bilirubin excretion causes are as follows 
 
A) ANATOMICAL ABNORMALITIES 
BILIARY TRACT OBSTRUCTION 
Causes include biliary atresia, bileduct abnormalities, gall stones, 
choledochal cyst.  
BILIARY ATRESIA  
It is the most common cause of obstructive jaundice in infants, it may be 
extra hepatic or intrahepatic.. Intahepatic type is mostly associated with 
syndromes namely Alagille and Aagnes syndrome.  
a) Extrahepatic biliary atresia  
Extrahepatic may be present as alone or it may be associated with trisomy 
13 or 18 or polysplenia 
More common  than intrahepatic biliary atresia.Stools are cheesy white 
colored.In histopathology of liver there will be periportal fibrosis and 
proliferation of bileduct. Scintigraphy of hepatobiliary system and PCLB along 
with visualisation at the point of operative cholangiography provide definitive 
information.kasai operation should be done before 2 months of age. 
b) Intrahepatic biliary atresia 
Intahepatic type is mostly associated with syndromes namely Alagille, 
Aagnes syndrome.Liver histopathology shows inflammatory changes with 
hypoplasia of bile canaliculi. 
Other causes are non syndromic paucity of intrahepatic bile duct, bile 
duct stenosis, or rupture of bile duct, lymph node enlargement, hemangiomas, 
pancreatic cysts and cystic fibrosis. 
B) INFECTIOUS CAUSES: 
Viral hepatits B&C, giant cell neonatal hepatitis, Epstein barr virus, 
Adenovirus, Coxsackie virus, Rubella, Echovirus, CMV 
C) BACTERIAL CAUSES : 
Syphilis, Staphylococcus, Tuberculosis,  Listeria, E.coli, Streptococcus. 
D) PARASITIC CAUSES: 
Toxoplasma 
E) DRUGS 
Vitamin k in large doses,kanamycin cause jaundice by blocking Y 
acceptor Protein. novobiocin, moxalactam, gentamycin, chloramphenicol 
competes with glucuronyl transferase, salicylates blocks bilirubin binding sites 
of  bilirubin. oxytocin usage in mother causes hyperbilirubinemia. 
F)METABOLIC CAUSES: 
Dubin Johnson syndrome, Rotor syndrome, Galactosemia, Tyrosenimia, 
Alpha 1Aantitrypsin deficiency, Cystic fibrosis, Hemochromatosis, Zellweger 
syndrome, storage disorders, Fructosemia, Bylers disease 
G) OTHER CAUSES : 
Prolonged parenteral nutruition, erythroblastosis fetalis, infants supported 
on ECMO. 
H) INSPISSATED BILE SYNDROME 
It is commonly seen in babies suffering from RH( hemolytic disease).It is 
due to transient difference between the maturity of  excretory and conjugatory 
functions of hepatocytes.The syndrome improves gradually once the Rh 
hemolytic disease is treated
.(75
) 
NEONATAL HEPATITIS 
The important cause accounting for 40% is idiopathic neonatal hepatitis. 
Infections such as viral, spirochetal, parasitic infections also contribute to 
neonatal hepatitis. Bile stained stools are present. Enlargement of liver and 
spleen is present. Viral infections such as Echovirus, Coxsackie B and Herpes 
simplex will present as fulminant hepatic failure. Giant cells will be present in 
histopathological examination. Hepatitis B virus acquired  by the neonate may 
also cause neonatal hepatitis.   
PERSISTENT NEONATAL JAUNDICE: 
Physiological jaundice disappears at three weeks of age but it may persist 
beyond three weeks of age due to indirect or direct hyperbilirubinemia. 
Breastmilk Jaundice, Gilbert Syndrome, Hypothyroidism, pyloric 
stenosis, malaria, cephalohematoma, Down’s syndrome, Urinary tract infection,  
Crigler Najjar Syndrome are the causes of  persistent prolonged indirect 
hyperbilirubinemia. 
Neoenatal hepatitis, insipissated bile syndrome, sepsis, malformation, 
metabolic disorder, total parenteral nutritionare the causes of prolonged direct 
hyperbilirubinemia 
CLINICAL PRESENTATION: 
HISTORY : any family history of jaundice, anemia, splenectomy, liver 
disease. Siblings with jaundice or anemia,  maternal illness during pregnancy, 
maternal drug intake, mode of delivery should be asked. 
Frequency of stooling, adequate intake of milk, vomiting. 
PHYSICAL EXAMINATION: 
Jaundice progresses in head to foot direction,  highest bilirubin levels are 
typically associated with yellowish discoloration of palms and soles. It is 
detected by applying finger pressure to blanch the skin in order  to notice the 
color of subcutaneous tissue and skin for serum bilirubin levels Visual 
inspection is not a reliable indicator.For inspection of sclera and eyes baby 
should be slightly moved front and back with support there by stimulating the 
vestibular apparatus eyes  will open.The cephalocaudal progression of jaundice 
is apparently related with respect to the skin thickness.it is necessary to  
examine all neonates twice a day in good day light to detect hyperbilirubinemia. 
IUGR babies  are more prone to develop jaundice. Microcephaly 
associated with intrauterine infections. Any cephalhematoma, bruisisng, or 
other enclosed hemorrhages, any pallor, petechiae, hepatosplenomegaly, 
omphalitis, chorioretinitis, evidence of hypothyroidsm. 
  
  
CLINICAL EXAMINATION OF NEONATAL JAUNDICE 
 
  
INVESTIGATIONS: 
Screening of total serum bilirubin, blood type, Rh typing, and antibody 
screening of the mother. 
Blood type, Rh typing, direct coombs test, peripheral smear for RBC 
morphology, hematocrit, direct bilirubin levels. 
If evidence in support of hemolysis, G6PD screening.  
Transcutaneous bilirubinometer 
PRINCIPLE-Computerised spectrophotometry. 
The circulating bilirubin in infants peaks at 3 – 4 days of age, at that time 
almost all babies are discharged. Hence portable transcutanoeus bilirubin 
monitors can be used to assess the neonatal jaundice
.( 14 ) ( 19 )
Transcutaneous 
bilirubin can be measured using Bilicheck 
( 15 ), (18 )
 it is reported that the value 
may changes depending on the site of sampling, degree of prematurity and skin 
colour. 
It cannot be used to assess the severity of jaundice in  neonates 
undergoing phototherapy
( 16 ), (17 )
 . Transcutaneous bilirubinometer can be used 
as a screening tool in assessing neonatal jaundice ( 12 ) 
  
 TRANSCUTANEOUS BILIRUBINOMETER 
 
  
HIGH PERFORMANCE LIQUID CHROMOTOGRAPHY is the gold 
standard choice of measurement of total serum bilirubin, but this method is used 
only in research laboratories  
CARBON MONOXIDE MEASUREMENT. 
etCO measurement  carbon monoxide is produced in equi molor 
concentration to bilirubin production and its measurement in breath can be done 
(12 )
 
Icterometer-used by inexperienced health workers by matching color 
codes with the skin color. 
BILIMETER 
Micro centrifuged sample of blood is taken in a capillary tube  which 
gives instant digital value. 
ADDITIONAL INVESTIGATIONS 
Evaluation for sepsis, congenital infections, screening for metabolic 
disorders, thyroid function. 
RED FLAG SIGNS IN  JAUNDICE 
• Jaundice appearing before 24 hours of of life 
• Rising serum bilirubin levels more than 0.2mg/dl/hr 
• Serum bilirubin levels requiring phototherapy 
• Associated with vomiting, letharygy, poor feeding, apnea, tachypnea, 
temperature instability, persistence of jaundice more than 8 days in tyerm 
infant and 14 days in pretterrm infant. 
• Previous sibling with jaundice, significant bruising, east asian ethnicity 
• Lower gestational age, isoimmune or other hemolytic disorders. 
Nomogram: The most commonly used  nomogram in assessment of 
neonatal hyperbilirubinemia is Bhutani’s nomogram. Age of the baby in hours 
is represented in X axis and the total serum bilirubin in Y axis.Neonates were 
divided into high risk,medium risk and low risk. 
  
 BHUTANI NOMOGRAM 
 
 
 
 
 
 
 
                         
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TREATMENT: 
Phototherapy, exchange transfusion, intravenous immune globulin, drugs 
and albumin therapy. 
 PHOTOTHERAPY: 
Bilirubin is absorbed in the wavelength of 400-500 nm and blue lamps 
with a output at 425-475 nm are efficient for phototherapy 
( 21), (26)
 
1. MECHANISM OF PHOTOTHERAPY: 
a) Photoisomerisation 
Unconjugated bilirubin (4z, 15z,) is converted to (4z,15e) which is less 
toxic and easily excreted
.(35) (40)
  Photoisomers make up 20% of biliurbin after 12 
hours of initiation of phototherapy The amount of  irradiance used is 
6microwatt/cm
2
/nm. 
b) Structural isomerisastion 
  It is due to the intramolecular cyclisation leading to lumirubin 
conversion. Once lumirubin is formed, it cannot be reabsorbed which makes up 
2-6% of bilirubin concentration during phototherapy
.(27)(34
) 
Irradiance : 6-12microwatt/cm
2
/nm. This is the most important pathway 
for lowering serum bilirubin. 
  
c) Photo-Oxidation 
It converts bilirubin to polar products which is excreted in urine
( 22,32) 
It is the least effective mechanism of  phototherapy. 
2. FACTORS FAVORING PHOTOTHERAPY : 
Irradiance, spectrum of light, distance from the infant,  area under 
exposure
( 25, 37)
 
A. Irradiance : conventional phototherapy 8-12microwatt/cm2/nm 
B. Intensive phototherapy : 30microwatt/cm2/nm 
C. Spectrum Of Light : 430-490 nm 
D. Distance From The Infant 
-Conventional  phototharepy: 20cm 
-Intensive phototherapy : 10 cm 
E. Area Under Exposure :  Eyes should be covered with biliband, 
frequent positional change every 2 hours, hydration.( 27) (39) 
Using high intensity gallium nitride light emitting diodes –intensive 
phototherapy can be given.  
  
3.TYPES OF PHOTOTHERAPY : 
A. SINGLE SURFACE PHOTOTHERAPY(SSPT): 
The infant is exposed to light source from either above or below in single 
surface phototherapy. 
B. DOUBLE SURFACE PHOTOTHERAPY: 
It is more effective than SSPT. The infant is exposed to light source from 
both above and below. Fibre optic  bilibankets provide additional effectiveness 
and through halogen bulbs phototherapy is provided from above. In our country 
Compact Florescent Tubes are most commonly used. 
Light banks: Alternating blue and fluorescent lights. In case of severe 
hyper bilirubinemia, neo blue phototherapy lights are used. Bulbs should be 
changed every three months. 
C.SPOT PHOTOTHERAPY :  
It is used for infants under radiant warmers
(28,37)
 
D.FIBREOPTIC BLANKETS :  
It is used for both single and double surface phototherapy. 
4. MONITORING OF CHILD UNDER PHOTOTHERAPY : 
In case of incubator usage distance from baby to light should be 5-8 cm, 
and temperature is monitored in servo mode. 
Fluid : 10-20% extra fluid should be given, baby should be weighed twice 
a day.
(24,32)
 
Home Phototherapy : It is effective and cheaper. Implemented with 
fibreoptic blankets, candidates for home phototherapy are breastfed infants. 
AAP recommends home phototherapy only for newborns within phototherapy 
optional range.
( 30, 32)
 
5. INDICATIONS FOR PHOTO THERAPY 
Infants weight between 1 to 1.5kg- Total serum bilirubin levels 7 to 
9mg/dl 
Infants weight between 1.5 to 2kg- Total serum bilirubin levels 10 to 
12mg/dl 
Infants weight between 2 to 2.5kg-  Total serum bilirubin levels 13 to 15 
mg/dl 
PROPHYLACTIC PHOTO THERAPY 
ELBW infants,severely bruised infants,hemolytic disease of newborn. 
  
CONTRAINDICATIONS FOR PHOTOTHERAPY 
In case of direct hyperbilirubinemia caused by obstructive jaundice or 
liver disease  phototherapy is contraindicated. Bronze baby syndrome occurs 
due to bronze pigment which is toxic.  
SIDE EFFECTS OF PHOTO THERAPY  
a. Insensible water loss it  may be up to 40 percent for term infants 
and 80 to 180 percent for preterm infants. 
b. Redistribution of blood flow as it increases blood flow in left 
pulmonary artery and cerebral arteries. 
c. Diarrhoea –increased bilesalts and unconjugated bilirubin 
d. Hypocalcemia-because of secretion of melatonin from pineal 
gland. 
e. Tanning of skin,retinal damage,mutations, DNA strand breaks, 
tryptophan is reduced in aminoacid solutions exposed to 
phototherapy. 
f.  Reduced maternal infant interactions 
  
ROLE OF SUNLIGHT IN NEONATAL HYPERBILIRUBINEMIA
(75)
  
The phototherapy wavelength should be in the range of 400nm-500nm.  
Sunlight  is not effective because UVA and UVB are absorbed in the 
atmosphere. Sunlight exposure can cause skin damage
.(75
)thus sunlight for the 
treatment of neonatal hyperbilirubinemia is neither safe nor effective.           
 EXCHANGE TRANSFUSION ( 42) 
INDICATIONS FOR EXCHANGE TRANSFUSION 
a. To remove antibody and sensitized RBCS. 
b. To correct anemia in hydrops fetalis 
( 47) 
c. Phototherapy unable to prevent rise in bilirubin levels 
IN HEMOLYTIC DISEASE 
a. Cord bilirubin level>4.5mg/dl and cord hemoglobin level<11g%. 
b. Rise in bilirubin level >1mg/dl/hr inspite of phototherapy 
58 
c. Bilirubin level >20mg/dl 
d. Progression of anemia 
( 53 )
 
 
MECHANISM OF EXCHANGE TRANSFUSION 
This method removes partially hemolysed and antibody coated RBCS and 
replace with donor RBCS lacking the sensitizing antigen. bilirubin is also 
removed from the plasma. The remaining extravascular bilirubin bind with 
albumin in the exchanged blood and excreted. 
( 50 )
 
PROCEDURE: 
Fresh blood to be used<7days old,in case of Rh hemolysis and ABO 
incompatability O negative or Rh compatible blood with mother and infant 
crossmatched against mother and infant blood group.Incase of nonimmune 
hemolysis blood is typed and crossmatched against plasma and red cells of 
infant.   
BLOOD VOLUME REQUIRED: 
Double the blood volume of infant(normal blood volume 80ml/kg)
(57) 
Infant is placed under servo controlled radiant warmer ,vitals should be 
monitored with intravenous cannula  insitu. The blood should be warmed to 
37degree. Under strict aseptic precautions umbilical cord is softened with saline 
soaked gauze to locate the vein and to insert the catheter.Most of the exchanges 
are done by push pull technique.Blood should be removed in small aliquots of 5 
to 10 ml for <2kg and more than 20 ml for >2kg. The recommended time is 
1hr.After the exchange transfusion phototherapy is continued and bilirubin is 
checked for every 4 hrs.
(55) 
COMPLICATIONS OF EXCHANGE TRANSFUSION 
HYPOGLYCEMIA-Glucose concenteration of CPD blood is around 250 
to 300mg% hence stimulate insulin secretion and cause hypoglycemia. 
HYPOCALCEMIA AND HYPOMAGNESEMIA-citrate in CPD blood 
binds ionic calcium and magnesium
(54)
 
HYPERKALEMIA- potassium levels higher in store pRBCs. 
ACID BASE IMBALANCE- Citrate in blood metabolized to alkali. 
Incase of sick infants acidosis occurs. 
BLEEDING-Thrombocytopenia, deficient clotting factors. 
INFECTION-Hepatitis, Cytomegalovirus, HIV, Malaria, Bacteremia 
HEMOLYSIS- due to overheating of blood. 
GRAFT VERSUS HOST DISEASE- maculopapular rash, eosinophilia,  
lymphopenia.  This can be prevented using irradiated blood. 
  
 INTRAVENOUS IMMUNOGLOBULIN 
High dose immunoglobulin can be given (0.5 to 1g/kg/dose) repeat in 
12hrs,  possibly acts by reducing hemolysis in both Rh incompatability and 
ABO incompatability 
RHO(D)IMMUNE GLOBULIN  can be given to mothers at 28 weeks 
and again with in 72 hrs of delivery who were rh negative and spouse Rh 
positive.
(75)
 
DRUGS 
METALLOPROTOPRPHYRINS  
A)  Tin-mesoporphyrin 
Tin is a competitive inhibitor of heme oxygenase..The  rate limiting 
enzyme in bilirubin production is hemeoxygenase.Side effects includeskin 
rashes, hepatic and renal toxicity. 
B) Zinc it acts by decreasing enterohepatic circulation. 
C) Oral agar can be used as they act by reducing enterohepatic 
circulation 
D)  Orotic acid acts by promoting bilirubin conjugation.Its utility is 
limited due to high cost. 
E) Phenobarbitone can be used  as it acts by inducing microsomal 
enzyme, increasing bilirubin conjugation ,increasing  bileflow and excretion.It 
is used in the treatment of  in Crigler najjar syndrometype 2. 
 F) Cholestyramine  can be used in the treatment of neonatal hyper 
bilirubinemia 
Which enhances the excretion of bilirubin and bilesalts hence by 
decreasing enterohepatic circulation.Side effects are constipation and 
hypercholremic acidosis.
(75)
 
 Albumin infusion 
5%salt free albumin can facilitate effective removal of bilirubin.it can be 
used before exchange transfusion,.but the utility is limited due to high cost and 
rare risk of transmission of viral infections
(75)
 
COMPLICATIONS OF NEONATAL HYPERBILIRUBINEMIA 
KERNICTERUS - BILIRUBIN ENCEPHALOPATHY is a neurologic 
syndrome due to the deposition of indirect bilirubin in the cranial nerve nuclei 
and basal ganglia and it also refers to yellowish staining  of the brain by 
unconjugated bilirubin together with neuronal injury. Incidence is 30% in 
infants with  bilirubin levels>25mg/dl and untreated hemolytic  disease. 
( 53 ) ( 64 )
 
PATHOPHYSIOLOGY 
It is multifactorial. 
a. unconjugated bilirubin levels.>20mg/dl
( 12 )
 
b. albumin levels-one gram of albumin will bind 8.5 mg of 
bilirubin,binding decreased in sick and premature infants.
( 61)
 
c. blood brain barrier integrity is disrupted in hyperosmolarity, 
asphyxia, hypercarbia, premature infants 
( 10 ) 
d. neuronal susceptibility-basal ganglia, cranial nerve nuclei 
mainly 8
th
 cranial nerve nuclei, cerebellar nuclei, 
hippocampus and anterior horn cells.
(63) 
e) sepsis, hypoglycemia, large doses of VitK 
f) trauma, cephalhematoma, dehydration 
g) Hepatitis. 
 
 
 
 
 
 
 
 
 
 
MECHANISM OF KERNICTERUS 
  
 
 
 
CLINICAL FEATURES 
Early phase: hypotonia, lethargy and high pitched cry  
Intermediate phase: hypertonia of  extensor muscles (opisthotonus), 
irritability, fever and seizures .Most of the infants die in this phase.
( 10 ) 
Advanced phase : hypotonia, shrill cry, apnea, seizures, coma and death.
( 
60) 
Other signs includes setting sun sign, fever, abnormal moro response only 
extension of arms will be there no flexion component followed by rolling of 
eyeballs. 
CHRONIC BILIRUBIN ENCEPHALOPATHY 
Infants surviving acute phase leads to choreoathetosis, sensorineural 
deafness, dental defects and impaired cognitive functions, delayed motor skills, 
upward gaze palsy.
( 58)
 
BIOCHEMICAL DETERMINANTS OF BILIRUBIN 
ENCEPHALOPATHY 
1) Bilirubin level more  than 25mg/dl. 
2) Bilirubin protein ratio3.5 or more. 
3) HBABA dye binding capability<50%. 
4) Salicylate saturation index of 8. 
5) SephadexG25 measures both free and boun bilirubin to albumin, if  
the level of both free and bound bilirubin is less thano.1mg/dl then 
the sephadexn  column is not yellow stained. 
6) Binding of bilirubin to RBC >4mg/dl.  
7) Peroxidase method invovinlves measuring free bilirubin>20nmol/L 
Kernicterus and hearing: 
In BERA there is significant suppression of all waves there will be 
increased latency in I,III,IV,V waves. 
PROGNOSIS 
Among affected infants, 80% have spastic quadriplegia, deafness, 
choreoathetosis, mental retardation and more than 75% of infants die
.(57)
 
PREVENTION 
a. universal screening of hyperbilirubinemia in 24 to 48 hrs after 
birth. 
b. follow up if the infant is discharged earlier than 48hrs. 
c. identify the risk factors. 
d. bilirubin levels should be analysed by measuring serum bilirubin 
levels not clinically. 
e. delay in initiating treatment 
f. failure of giving adequate importance to history such as lethargy  
and poor feeding.
(54) ( 59) 
g) adequate breast feeding
(75) 
h) treatment of comorbidities such as sepsis, hypothermia, 
hypoglycemia, avoiding large doses of VitK
75 
 Differential diagnosis 
a) sepsis 
b) cerebral palsy 
c) birth asphyxia 
d) bacterial meningitis 
e) head trauma 
HYDROPS FETALIS 
Abnormal and increased  collection of fluid  in  more than two fetal 
compartments (placenta, pleura, skin, pericardium, peritoneum).
( 67) ( 66 )
 
Hydrops fetalis incidence is in the decreasing trend nowadays due to the early 
recognition and treatment. 
 
CAUSES 
 HEMATOLOGIC  CAUSES 
D antigen contribute for >90% of cases  and the remaining cases are  due 
to E  or C antigen. Infusion of Rh  positive blood  to  Rh  negative woman 
through blood transfusion ,  abortion, delivery , mother will be sensitized and 
start producing IgM antibodies initially and later IgG antibodies which can 
cross the placenta and cause hemolytic manifestations. Other causes are 
homozygous thalassemia, twin to twin transfusion, leukemias and G6PD 
deficiency. 
( 68 ) 
 
 
 
 CARDIOVASCULAR CAUSES:  
Heart block, arrhythmias, hypoplastic left heart disease,  myocarditis,  
endocardial fibroelastosis, cardiac masses, premature closure of foramen ovale. 
 RENAL CAUSES: 
Hydronephrosis, renal vein thrombosis, renal hypoplasia, urinary tract 
obstruction. 
 INFECTIOUS CAUSES 
Syphilis, Rubella, CMV, Adenovirus, Hepatitis, Herpesvirus, 
Adenovirus, Leptospirosis, Parvovirus, Chagas disease. 
 PULMONARY CAUSES 
Congenital diaphragmatic hernia, cystic adenomatoid malformations, 
chylothorax. 
 PLACENTA OR CORD ABNORMALITIES 
 GASTROINTESTINAL CAUSES 
Meconium peritonitis, atresia of intestine. 
( 67 )
 
 CHROMOSOMAL ABNORMALITIES 
  
CLINICAL FEATURES 
The severity of the disease range from  pallor to severe anemia, massive 
hepatosplenomegaly, heart failure, respiratory distress, jaundice, bilirubin 
encephalopathy, hypoglycemia, petechiae , DIVC. ( 64) 
INVESTIGATIONS 
Blood grouping and typing of mother and infant, coombs test, redcell 
antibody titres, RBC indices, hemoglobin electrophoresis, ESR, Betke stain to 
identify fetal red cells, fetal echo, ultrasonogram, lupus tests, fetal blood 
sampling for karyotype, CBC, hemoglobin, electrophoresis, cultures, PCR, 
DNA studies, albumin, Xrays, LFT, amniocentesis for viral infections, 
metabolic studies. ( 62 ) 
MANAGEMENT OF FETUS 
When the hematocrit is less than 30% umbilical vein transfusion is done 
.Packed RBCS cross matched against mother serum  are given by slow push 
method . Leukoreduction and irradiation should be done to prevent graft versus 
host disease. Survival rate is 89% complications include preterm delivery, fetal 
distress, perinatal death. ( 12) 
MANAGEMENT OF  NEWBORN 
Fresh low titre O blood group leukoreduced and irradiated should be 
available. If signs of hemolysis are present then immediate resuscitation, 
supportive therapy should be started such as small transfusion of RBC’s, 
volume expansion for hypotension, acidosis correction with sodium bicarbonate 
and ventilation support  for respiratory failure. Most severe cases require 
exchange transfusion.  
INTRAVENOUS IMMUNOGLOBULIN 
Reduces the necessity for duration of phototherapy, exchange transfusion 
and length of hospital stay 
PREVENTION 
ANTI D (300 microgram) administration  at 28 weeks of gestation and 
within 72 hrs of delivery in Rh negative mothers sensitized with RH positive 
infants
. ( 53 )
 
  
REVIEW OF LITERATURE 
Alaeidin et al study 
(73) 
was carried out on 94 healthy newborns(47 FT 
and 47 PT) from the obstetrics department and NICU of Ismailia General 
Hospital. Babies were chosen according to specific inclusion and exclusion 
criteria. 
The study group was followed up clinically and by laboratory 
investigations. Total serum bilirubin in umbilical cord was measured at birth, 
and followed up using transcutaneous bilirubinometry during the first week of 
life to find out babies developing significant hyperbilirubinemia and in need for 
treatment. 
The gender distribution of  the study showed that baby boy was 
insignificantly higher than the baby girl . The mean gestational age was 
38.70 ± 1.38 weeks in full term compared to 35.62 ± 0.64 in preterm. The mean 
birth weight was 3.302 ± 0.207 Kg in full term compared to 2.936 ± 0.207 Kg. 
Regarding the needed treatment among study population, it was found 
that 40.4% of preterm  and 29.8% of full term needed phototherapy and no one 
of both groups needed exchange transfusion. 
Total and direct cord bilirubin was slightly higher among full term 
compared to preterm. However these differences were not significant. 
The cut off points for total cord bilirubin in preterm  and full termwas 
2.05 and 2.15 mg/dl respectively. 
The strongest predictor of receiving phototherapy was total cord bilirubin 
compared to gestational age, ABO, incompatibility, Rh incompatibility and sex. 
The study concluded that during first week of life , cord blood bilirubin is 
indicative of severity of  jaundice in  healthy full term and late preterm  without 
complications. Indication for phototherapy in  full term and  preterm   was cord 
blood bilirubin levels ≥2.05 mg/dl and 2.15 respectively  and also the  presence 
of mother/baby blood group incompatibility . 
Gurudeepsingh et al
(72)
 study 
The study group consisted of neonates delivered in MMIMSR -100 full-
terms Appropriate for gestational age . 
Incidence of  hyperbilirubinemia was 14% with  Mean umbilical cord 
blood  bilirubin was 1.63±0.73. Neonatal  hyperbilirubinemia and mode  of  
delivery (p>0.005) was not statistically significant. neonatal hyperbilirubinemia 
and sex of the baby and maternal age (p>0.05)was not  statistically significant.  
There is no association between mother’s blood group and the increased 
risk of hyperbilirubinemia in neonates. 
Association between neonatal hyperbilirubinemia and increasing 
umbilical cord blood bilirubin (p= 0.001) was statistically significant. Using 
umbilical cord blood bilirubin level of 1.9 mg/dL hyperbilirubinemia showed 
sensitivity of 92.8%, specificity of 83.7% , negative predictive value of 98.6% 
and positive predictive value of 48.1%.  the study showed that umbilical cord 
blood bilirubin is an indirect indicator of serum bilirubin to indicate the 
development of neonatal hyperbilirubinemia and decide need for intervention in 
healthy term neonates.            
             Amar Thakshande et al study
(71)
 was conducted in 200 healthy term 
neonates born in KHS hospital sewagram. The study showed  the incidence of 
pathological hyperbilirubinemia was 28 ( 6% ) and  there were no significant 
differences between the cases who did and the cases who did not develop 
significant hyperbilirubinemia with respect to these factors (such as Rh 
incompatibility, delivery route , birth weight ) and  is associated with the risk of 
hyperbilirubinemia . But there exist a differences between the neonates affected 
with significant hyperbilirubinemia and unaffected neonates with respect to sex, 
history of siblings with hyperbilirubinemia , cord bilirubin leve1.  
These  results are in good agreement with other studies but differ from 
others especially regarding sex. In this study, the cord bilirubin level of >2 
mg/dL has the highest sensitivity (71.5%), and this critical bilirubin level had a 
very high (98.1%) negative predictive value and fairly low (45.4%) positive 
predictive value . The study showed that  cord bilirubin values predicts the risk 
of  hyperbilirubinemia and minimize the hospital stay. 
Nagwa et al conducted a correlational study  between umbilical cord 
serum bilirubin (UCB) & subsequent development of hyperbilirubinemia.  The 
risk of developing severe hyperbilirubinemia is seen in Newborns presenting 
cord blood  bilirubin levels > 4mg/100ml were  followed up and reassessed. The 
mean serum bilirubin levels was >16mg/dl at 72 hours of postnatal age with a 
peak level of 17 ±4.3mg/dl at 68± 17.5 hours of postnatal age. There is a strong 
association between the cord blood bilirubin and the newborn's bilirubin level at 
different postnatal ages.  In the study, the cutoff point for the cord blood  
bilirubin was 2.0mg/dl. With this cutoff point, whenever values that were 
greater than or equal to 2mg/dl, indicates the  probability of more than 50%  for 
the need of phototherapy . 
Rosenfeld et al analyzed a group of 108 full-term newborn and  
concluded that babies with an umbilical cord blood bilirubin level of < 2mg/dl 
had a 4% chance of developing significant jaundice, in comparison with a 25% 
risk of developing jaundice presented by the ones with levels > 2mg/100ml and 
need for phototherapy. 
 
Knudsen  et al,  carried out a study to demonstrate that newborns with  
clinical jaundice have higher levels of  umbilical cord blood bilirubin and those 
with  cord blood bilirubin >2mg/dl required phototherapy later. This proved that 
it is possible to define  newborn risk group for developing neonatal severe 
hyperbilirubinemia  by measuring umbilical cord bilirubin. 
Alpay et al,  observed that serum bilirubin >6mg/dl on the first day of life 
had 90% sensitivity of predicting a subsequent TSB >17mg/dl between 2
nd
 and 
5
th
 day of life. At this critical serum bilirubin value, the negative predictive 
value was 97.9%.  No cases with TSB of 2mg/dl had the highest sensitivity 
(89.5%), and this critical bilirubin level had a very high (98.7%) negative 
predictive value and fairly low (38.6%) positive predictive value.  
Eswara et al prospectively determined the critical cord serum bilirubin 
level to predict significant hyperbilirubinemia in healthy term newborns. In 
their study a total 51 of 288 (18.09%) were found to have significant 
hyperbilirubinemia and the umbilical cord bilirubin level cut off point was 2 
mg/dl with  good sensitivity (94.12), specificity (90.9%), negative predictive 
value (98.59%) and  positive predictive value (69.57%) . 
Knudsen et al
(77)
 reported umbilical cord serum bilirubin concentration as 
a predictor of subsequent jaundice was studied in 291 newborns. It was possible 
to define subgroups of infants with significantly higher or lower risks of 
developing  jaundice. If cord bilirubin was below 1.17 mg/dl, 2.9% became 
jaundiced as opposed to 85% if cord bilirubin was above 2.3 mg/dl. 
Furthermore, 57% of jaundiced infants with cord bilirubin > 2.3 mg/dl required 
phototherapy, but if cord bilirubin was< 2.3 mg/dl it is only 9%. Cord blood  
bilirubin level >2.5 mg/dl is a high risk indicator for predicting neonatal 
hyperbilirubinemia.  
Bernaldo et al  reported that the indirect cord blood bilirubin levels 
indicates the severity of  jaundice in  full-term newborns without complications, 
up to  third day of life. Levels that ≥2 mg/100 ml indicates 53% probability of 
developing hyperbilirubinemia requiring phototherapy. 
Zakianahar 
(73)
 et al study showed that Cord blood bilirubin level of ≥ 
2gm/dl has a sensitivity of 70% and specificity of 89% in predicting the risk of 
neonatal hyperbilirubinemia. 
Ramprasanth et al study was conducted to assess the usefulness of the 
cord blood bilirubin estimation as a predictor of subsequent 
neonatal hyperbilirubinemia in a healthy term infants who require phototherapy. 
A prospective cohort study 100 term newborn was conducted at tertiary 
care centre.  
Cord blood bilirubin > 2.15mg/dl has a sensitivity of 65% and specificity 
of 65% % in prediction of neonatal hyperbilirubinemia.  
A study by Suchonska et al involving 187 healthy term infants  showed 
the mean cord blood bilirubin was 1.30mg% and the association between cord 
blood bilirubin level and subsequent risk of developing neonatal 
hyperbilirubinemia was statistically significant  with p value <0.005. 
Jayalakshmi et al 
(70)
   study involving  567 term neonates  showed the 
association between  cord blood bilirubin level and neonatal hyperbilirubinemia 
was studied  with receiver operating characteristic analysis a cutoff value of 
>1.89mg% had highest sensitivity and high negative predictive value. The study 
was concluded saying that noninvasive cord blood bilirubin measurement can 
be used as a simple tool in identifying infants at risk for developing significant 
hyperbilirubinemia. 
Knupfer
(78)
 et al study showed that  umbilical cord blood bilirubin is a 
good predictor of developing  neonatal hyperbilirubinemia  and showed that 
when cut off value of cord blood bilirubin is 3mg/dl it revealed a sensitivity of 
70.3% and a negative predictive value of 65.6%. 
Singal Vikram et al
(80)
 study involved 500 infants and the study showed 
the sensitivity of  developing  neonatal hyperbilirubinemia was 90% when the 
cord blood bilirubin level was more than 1.9mg%. 
Nilesh Ahire and Ravindra et al
(76)
 studied 100 infants in predicting 
neonatal  hyperbilirubinemia by sampling cord blood bilirubin levels. The study 
showed the  sensitivity of 100% in developing hyperbilirubinemia when the 
cord blood bilirubin level  was more than 3mg%. 
Sun Wangyl, Liangjf, Dulz et al  studied the cord blood bilirubin levels in 
predicting neonatal hyperbilirubinemia  conducted in 194 infants and  it was 
found that cord blood bilirubin levels >2.5mg/dl had the sensitivity of 68.27% 
in predicting neonatal hyperbilirubinemia. 
  
 AIM OF THE STUDY 
 To study the sensitivity of cord blood bilirubin levels in predicting 
neonatal hyperbilirubinemia. 
OBJECTIVES 
 To statistically analyze the sensitivity of cord blood bilirubin levels in 
predicting neonatal hyperbilirubinemia. 
 To find out mean cord blood bilirubin level.  
NEED OF STUDY  
 To find out the term neonates who were at greater risk of developing   
neonatal hyperbilirubinemia. 
 To plan for early discharge. 
 To decrease the risk of readmission. 
  
MATERIALS AND METHODS 
STUDY POPULATION   
• All term newborn babies born In Govt Kilpauk Medical college during 
the study period will be assessed for inclusion and exclusion criteria and 
will be included in the study after obtaining written informed  consent.  
• Study design –A hospital based  prospective study  
• Study period – 6 months (April 2016 - September 2016) 
• Study population-180 
Inclusion criteria 
• Gestational age more than 37 weeks  
• Absence of significant illness requiring NICU admission  
•  Absence  of major congenital malformation.  
Exclusion criteria  
        Newborn born to mother prone for hemolysis (OA, OB, Rh 
incompatability) 
• Gestational age less than 37 weeks 
• Significant illness requiring NICU admission  
• Mother taking drugs causing neonatal hyperbilirubinemia. 
• Family history of jaundice, anemia, splenectomy, liver disease. 
• Maternal illness, gestational diabetes mellitus.  
• Calculation  of Sample size  
• Sample size was based on the study of sensitivity of cord blood bilirubin 
83% authored by Amar tak shande published in current paediatrics 2005 - 
2009. 
• Sample size was 180 based on the following  
• Expected sensitivity of cord blood bilirubin 83% 
• Desired accuracy 7%  
• Alpha error 5%  
Methodology 
          Approval from the Institutional scientific and Ethical committee of 
Government Kilpauk Medical College and Hospital Chennai was obtained. 
Newborns delivered in KMC who satisfy the inclusion criteria were included in 
the study. The parents were given counseling and informed consent was 
obtained from them for investigation and enrollment into the study. If at any 
point of time newborn was found to have parameters in the exclusion criteria 
then that newborn was excluded from the study. 
 
• Under strict aseptic precautions Cord blood samples were collected from 
all newborns for analysis of serum bilirubin levels and blood grouping 
typing with the protocol inclusion criteria. 
• These newborns were followed up for three days and the values of 
bilirubin on the third day were compared with cord blood bilirubin level. 
• Under strict aseptic precautions, 2ml of cord blood was  collected from 
the umbilical cord and sent to  investigations.  
• Serum bilirubin assessment  
• Blood grouping and typing. 
• 2ml of  venous blood was collected from the baby > 72 hours for 
assessment of serum bilirubin. 
PRINCIPLE : 
VADENDER BERGH’S TEST 
• Serum and cord blood bilirubin assessment was done by diazo method. 
2,5-dichorophenyldiazonium tetrafluroborate was the diazo reagent. This 
reagent is used to accelerate the reaction. Pink colour is formed due to 
reaction between bilirubin and diazotized sulphanilic acid in the acidic 
medium. Limitations of the test include blood sample size, reliability and 
accuracy interlaboratory variations are found around 10 to 15%.variations 
in conjugated bilirubin measurement involves 20%. 
STATISTICAL ANALYSIS 
IBM. SPSS statistics software 23.0 Version was being used to analyse the 
data obtained. Data descriptive statistics frequency analysis was carried out to 
describe the collected data. Categorical variables analysed with percentage 
analysis continuous variables were analysed with mean and standard deviation. 
The Sensitivity, Specificity, Positive predictive value and Negative predictive 
value were found by receiver operator curve analysis. Categorical variables 
association was computed with Chi-square test. In both of the above statistical 
tools the probability value above .05 is considered as significant level.  
  
RESULTS AND ANALYSIS 
The study was conducted in government Kilpauk medical college. The 
neonates who were satisfied with the inclusion criteria were included. The study 
was done in 180 Term neonates who were born in Govt Kilpauk medical 
college hospital. Study outcome as defined by total serum bilirubin of  more 
than or equal to15mg/dl after 72 hrs. All neonates required phototherapy and 
none required exchange transfusion. The incidence of neonatal 
hyperbilirubinemia in this study was 22.8% out of 180 term neonates. 
 
 
 
  
Male 
49% 
Female 
51% 
GENDER DISTRIBUTION 
 TABLE 1: 
CROSS TAB: GENDER & SERUM BILIRUBIN 
SERUM BILIRUBIN 
GENDER >= 15 < 15 
Female 
 
51.2% 
 
50.4% 
Male 
 
48.8% 
 
49.6% 
 
 
 
 
 
 
 
 
 
 CHART-2 : 
GENDER Vs SERUM BILIRUBIN 
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Sr.Bilirubin with gender 
Female Male 
 Chi-Square Tests 
  Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson 
Chi-Square 
.009
a
 1 .923     
Continuity 
Correction
b
 
0.000 1 1.000     
Likelihood 
Ratio 
.009 1 .923     
Fisher's 
Exact Test 
      1.000 .532 
No. of 
Valid 
Cases 
180         
a. 0 cells (0.0%) have expected count less than 5. The minimum 
expected count is 20.27. 
b. Computed only for a 2x2 table 
In the present study, sex of the baby and neonatal hyperbilirubinemia was not 
statistically significant. 
  
 CHART-3 
MOTHER BLOOD GROUP 
  
In this study around 88 mothers had B blood group, 39 mothers had AB 
blood group and 53 mothers had A blood group. 
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MOTHER -BLOOD GROUP 
mother -blood group 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 
 
Valid 
A 53 29.4 29.4 29.4 
AB 39 21.7 21.7 51.1 
B 88 48.9 48.9 100.0 
Total 180 100.0 100.0  
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 baby-blood group 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 
 
 
 
 
Valid 
A 57 31.7 31.7 31.7 
AB 30 16.7 16.7 48.3 
B 74 41.1 41.1 89.4 
O 19 10.6 10.6 100.0 
Total 180 100.0 100.0  
 
In this study 74 neonates had B blood group,57 neonates had A blood 
group,30 neonates had AB blood group,19 neonates had O blood group. 
 
 
 
 
 
MODE OF DELIVERY 
  
 
 
 
TABLE 3 
LSCS 
12% 
LN 
88% 
82.9% 
89.2% 
17.1% 
10.8% 
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
>= 15 < 15 
Sr.Bilirubin with Mode of delivery 
LN LSCS 
MODE OF DELIVERY Vs SERUM BILIRUBIN 
Crosstab 
 
Sr.bilirubin Range 
Total >= 15 < 15 
 
 
 
 
 
 
Mode 
of 
delivery 
 
 
 
LN 
Count 34 124 158 
% within Sr. 
bilirubin 
Range 
82.9% 89.2% 87.8% 
 
 
 
LSCS 
Count 7 15 22 
% within Sr. 
bilirubin 
Range 
17.1% 10.8% 12.2% 
Total Count 41 139 180 
% within Sr. 
bilirubin 
Range 
100.0% 100.0% 100.0% 
 
 
Chi-Square Tests 
 
Value Df 
Asymp. Sig. Exact Sig. (2- Exact Sig. (1-
(2-sided) sided) sided) 
Pearson Chi-
Square 
1.165
a
 1 .281   
Continuity 
Correction
b
 
.653 1 .419   
Likelihood Ratio 1.088 1 .297   
Fisher's Exact 
Test 
   .285 .206 
No of Valid 
Cases 
180     
a. 0 cells (0.0%) have expected count < 5. The minimum expected count 
is 5.01. 
b. Computed only for a 2x2 table 
In this study 34 neonates born by normal vaginal delivery developed 
neonatal hyperbilirubinemia and 7 babies born by LSCS developed 
neonatal hyperbilirubinemia. 
 In the present study no statistically significant association was found 
between mode of delivery and neonatal hyperbilirubinemia. 
 
RELATIONSHIP BETWEEN CORD BLOOD BILIRUBIN LEVEL AND 
SERUMBILIRUBINLEVEL 
 Descriptive Statistics 
 
N Minimum Maximum Mean 
Std. 
Deviation 
C Bilirubin 180 .80 2.30 1.5425 .35993 
Sr.Bilirubin 180 7.0 18.7 12.428 2.6137 
Valid N 
(listwise) 
180     
 
In this study the mean of cord blood bilirubin level is 1.5425 mg/dl with 
standard deviation of 0.35993. 
In this study the mean serum bilirubin level is 12.428 mg/dl with the 
standard deviation of 2.6137 
 
 
 
 
 
 CORD BLOOD BILIRUBIN RANGE 
0 - 0.9 1.1% 
1 - 1.9 83.9% 
2 - 2.9 8.3% 
>= 3 6.7% 
 
 The cord blood bilirubin in the range of 1 to 1.9mg/dl was found in 
majority of neonates (84%) 8% of neonates were in the range of 2 to 2.9mg/dl 
and 7% of  neonates had more than or equal to 3mg/dl. 
1% 
84% 
8% 
7% 
Chart -4 :CORD BLOOD BILIRUBIN RANGE 
0 - 0.9 
1 - 1.9 
2 - 2.9 
>= 3 
  
CORD BILIRUBIN Sr.Bilirubin>= 15 Sr.Bilirubin < 15 
0 - 0.9  1.4% 
1 - 1.9 43.9% 95.7% 
2 - 2.9 34.1% .7% 
>= 3 22.0% 2.2% 
 
  
1.4% 
43.9% 
95.7% 
34.1% 
.7% 
22.0% 
2.2% 
0% 
10% 
20% 
30% 
40% 
50% 
60% 
70% 
80% 
90% 
100% 
>= 15 < 15 
C.Bilirubin with Sr.Bilirubin 
0 - 0.9 1 - 1.9 2 - 2.9 >= 3 
TABLE - 4: 
CORD BLOOD BILIRUBIN VS SERUM BILIRUBIN 
 
Sr.bilirubin Range 
Total >= 15 < 15 
C.Bilirubin 
range 
0 - 0.9 Count 0 2 2 
 % within Sr 
bilirubin Range 
0.0% 1.4% 1.1% 
1 - 1.9 Count 18 133 151 
 % within Sr. 
bilirubin Range 
43.9% 95.7% 83.9% 
2 - 2.9 Count 14 1 15 
 % within Sr. 
bilirubin Range 
34.1% .7% 8.3% 
>= 3 Count 9 3 12 
 % within Sr. 
bilirubin Range 
22.0% 2.2% 6.7% 
Total Count 41 139 180 
% within Sr. 
bilirubin Range 
100.0% 100.0% 100.0% 
 
 
 
 Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-
Square 
71.767
a
 3 .000 
Likelihood Ratio 61.992 3 .000 
Linear-by-Linear 
Association 
54.734 1 .000 
N of Valid Cases 180   
 
a. 4 cells (50.0%) have expected count less than 5. The minimum 
expected count is .46. 
 
 
 
 
 
 
 ROC CURVE 
 
 
 
 
Area Under the Curve 
Test Result Variable(s): C Bilirubin 
Area Std. Error
a
 Asymptotic Sig.
b
 
Asymptotic 95% 
Confidence Interval 
Lower 
Bound 
Upper 
Bound 
.969 .011 .000 .948 .990 
 
The test result variable(s): C Bilirubin has at least one tie between the 
positive actual state group and the negative actual state group. Statistics 
may be biased. 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
Case Processing Summary 
Sr.Bilirubin Range Valid N (list wise) 
Positive
a
 41 
Negative 139 
Larger values of the test result variable(s) indicate for a positive actual state. 
a. The positive actual state is >= 15. 
 
DISCUSSION 
This study was conducted in Government Kilpauk Medical College 
Chennai. This is a renowned tertiary care teaching centre. Our study population 
comprises 180 newborns born in Govt Kilpauk Medical College Hospital. Out 
of 180 babies 91 were female babies and 89 were male babies .In the present 
study no significant difference (pvalue 0.923) was found between gender of the 
baby and neonatal hyperbilirubinemia..  This was in accordance with study by 
Amartak Shande, Gurudeepsingh, Eswara et al. 
Out of 180 babies 158 babies were delivered by labour naturalis and 22 
babies were delivered by LSCS. In the present study no significant difference (p 
value 0.281) in the development of neonatal hyperbilirubinemia was identified 
between the cases who  were born by LSCS and normal vaginal delivery. This 
was in accordance with study by Amartak shande, Gurudeepsingh et al. There 
was also no association between cord blood bilirubin and mode of delivery 
(pvalue0.515).About 1%of the study population had cord blood bilirubin in the 
range of <0.9,84% had cord blood bilirubin in the range 1 to1.9mg/dl and 8% 
had cordblood bilirubin in the range of 2to2.9mg/dl and 7%had cord blood 
bilirubin in the range of 3mg/dl and more than 3mg/dl. 
          The mean cord blood bilirubin in the study was 1.5425 
(+0.35993to0.35993-mg/dl). The mean serum bilirubin level in the present 
study was12.428mg/dl(+2.6137-2.6137) 
The use of the critical cord bilirubin level 1.85mg/dl will predict 
significant hyperbilirubinemia. 
The association between cord blood bilirubin level equal to or more 
than1.85mg/dl and neonatal hyperbilirubnemia was statistically significant 
(p.000). The relationship of cord bilirubin and serum bilirubin was studied. The 
probability that neonates with cord blood bilirubin level equal to or more than 
1.85mg/dl` would later develop hyperbilirubinemia ie, positive predictive value 
was 72.3%. 
The negative predictive value, the probability of non hyperbilirubinemia 
if the cord blood bilirubin less than 1.85mg/dl was 94.7%. The sensitivity of 
cord blood bilirubin in predicting neonatal hyperbilirubinemia was 82.9% (if a 
neonate become hyperbilirubinemic ,the probability that the cord blood bilirubin 
was higher than or equal to 1.85mg/dl).  
The specificity of cord blood bilirubin in predicting neonatal 
hyperbilirubinemia was 90.6%. With Receiver operating characteristic analysis, 
cord blood bilirubin level of equal to or more than 1.85mg/dlwas determined to 
have high sensitivity(82.9%).  
At this cord blood bilirubin level the negative predictive value was 
94.7%. out of 41 babies who developed neonatal hyperbilirubinemia only 7 
babies had serum bilirubin level<1.85mg/dl all others had cord blood bilirubin 
level more than or equal to 1.85mg/dl.Out of 139 babies who didn’t develop 
hyperbilirubinemia only 13 babies had cord blood bilirubin level morethan or 
equal to 1.85mg/dl.  
Out of 47 babies having cord blood bilirubin level more than or equal 
to1.85mg/dl 34 babies developed neonatal hyperbilirubinemia. Out of133 
neonates who had cord blood bilirubin less than1. 85mg/dl only 7 babies 
developed hyperbilirubinemia the present study goes well with the following 
studies. 
Gurudeepsingh etal
(72)
 study group consisted of neonates delivered in 
MMIMSR -100 full-terms Appropriate for gestational age .Incidence of  
hyperbilirubinemia was 14% with  Mean umbilical cord blood  bilirubin was 
1.63±0.73. neonatal hyperbilirubinemia and mode of  delivery (p>0.005) was 
not statically significant. Neonatal hyperbilirubinemia and sex of the baby and 
maternal age (p>0.05)was not  stastically significant. There is no association 
between mother’ s blood group and the increased risk of hyperbilirubinemia in 
neonates. 
Association between neonatal hyperbilirubinemia and increasing 
umbilical cord blood bilirubin (p= 0.001) was statistically significant. Using 
umbilical cord blood bilirubin level of 1.9 mg/dL hyperbilirubinemia showed 
sensitivity of 92.8%, specificity of 83.7% , negative predictive value of 98.6% 
and positive predictive value of 48.1%.  The study showed that umbilical cord 
blood bilirubin is an indirect indicator of serum bilirubin to indicate the 
development of neonatal hyperbilirubinemia and decide need for intervention in 
healthy term neonates.   
Eswara et al prospectively determine the critical cord serum bilirubin 
level to predict significant hyperbilirubinemia in healthy term newborns. In that 
study a total 51 of 288 (18.09%) were found to have significant 
hyperbilirubinemia. In this study, umbilical cord bilirubin level cut off point is 2 
mg/dl with  good sensitivity (94.12), specificity (90.9%), negative predictive 
value (98.59%), positive predictive value (69.57%). 
Zakianahar et al study showed that Cord blood bilirubin level of ≥ 2gm/dl 
has a sensitivity of 70% and specificity of 89% in predicting the risk of neonatal 
hyperbilirubinemia. 
The present study was also in accordance with the studies conducted by 
Ramprasath et al, Jayalakshmietal, Alpeyetal, Knudsenetal, Nilesh ahire et al, 
Aleiden et al., But the study conducted by Jayashree Vasudevan was not in 
accordance with the above the studies
74
. 
 
 
 
 
LIMITATIONS OF STUDY 
 Only healthy term babies were included in the study 
 Preterm babies and sick babies are not included in the study. 
 Babies prone for hemolysis were not included in the study. 
 Diazo method of measuring serum bilirubin involves interlab variability 
of the results. 
  
 CONCLUSION 
In the present study  it was concluded that cord blood bilirubin can be 
used as a noninvasive screening test to predict the neonates at risk for 
developing significant hyperbilirubinemia. 
In this study it was showed that there was a significant association 
between cord blood  
 Bilirubin level more than 1.85mg/dl and neonatal hyperbilirubinemia.No 
statistically significant association was found between gender,mode of delivery 
and neonatal hyperbilirubinemia 
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சுய ஒப்புதல் படிவம் 
இடம் :  அரசு கீழ்பாக்கம் மருத்துவக் கல்லூரி, சென்னை  
              எைது குழந்னதக்கு இரத்தத்தில்  மஞ்ெள் காமானை 
ஏற்படுவதற்காை வாய்ப்புகள் உள்ளதா என்பனத 
சதாப்புள்சகாடியிைிருந்து இரத்தத்னத எடுத்து ஆய்வு செய்து 
சகாள்வதற்கு ெம்மதம்  
 
 
 
 
 
 
 
 
 
 
  
b/o nathiya F A A 1.5 12.5 LN 
b/o  revathi M A B 1.9 17.1 LN 
b/o vanmathi F B B 1.95 16.4 LN 
b/o 
vijayakumari M B A 1 9.8 LN 
b/o chellam F AB  AB 1.3 10.2 LN 
b/o kodeswari M B B 1.25 9.2 LN 
b/o sowmiya M B AB 1.5 12.5 LN 
b/o subhashri F AB AB 1.1 11.5 LN 
b/o pushpa F B B 2.2 17.5 LN 
b/o rebecca F A A 1.87 13 LN 
b/o vasha M AB AB 1.6 12.2 LN 
b/o shalini F B B 1.87 13.4 LN 
b/o radha F B B 1 9 LSCS 
        
 
ABBREVIATIONS 
 
RES   – Reticulo Endothelial System 
RBC   – Red Blood Corpuscles 
PCLB  – Per Cutaneous Liver Biopsy 
SSPT   – Single Surface Phototherapy 
CFT   – Compact Flourescent Tubes 
HBABA  –  2-4’ Hydroxy Benzene Azo Benzoic Acid 
BERA  – Brain Stem Evoked Response Audiometry 
DIVC  - Disseminated Intravascular Coagulation 
PCR   – Polymerase Chain Reaction 
LSCS  - Lower Segment Caesarean Section 
  
 
 
 
 
 
 
 
